StockData
Q32 Bio Inc. logo

Q32 Bio Inc. (QTTB) stock

QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.63+0.34 (+4.10%)

Close on Nov 17, 2026Market cap $256.91MP/E –Yield –

Q32 Bio total assets

Total assets on the balance sheet at the end of each period.

Q32 Bio's total assets was $115.87M at Jun 30, 2026. For fiscal 2025 it was $61.78M, down 33.1% from the year before. The highest annual figure on record is $310.57M in fiscal 2019.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.78M-33.1%
FY2024Dec 31, 2024$92.33M+96.2%
FY2023Dec 31, 2023$47.06M-79.4%
FY2022Dec 31, 2022$228.47M+7.9%
FY2021Dec 31, 2021$211.72M-19.7%
FY2020Dec 31, 2020$263.74M-15.1%
FY2019Dec 31, 2019$310.57M+19.9%
FY2018Dec 31, 2018$259.09M+88.4%
FY2017Dec 31, 2017$137.53M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$115.87M+75.2%
Q1 FY2026Mar 31, 2026$63.68M-19.5%
Q4 FY2025Dec 31, 2025$61.78M-33.1%
Q3 FY2025Sep 30, 2025$57.78M-44.7%
Q2 FY2025Jun 30, 2025$66.12M-46.8%
Q1 FY2025Mar 31, 2025$79.07M-48.1%
Q4 FY2024Dec 31, 2024$92.33M+96.2%
Q3 FY2024Sep 30, 2024$104.54M-25.4%
Q2 FY2024Jun 30, 2024$124.21M-26.7%
Q1 FY2024Mar 31, 2024$152.33M-23.0%
Q4 FY2023Dec 31, 2023$47.06M-79.4%
Q3 FY2023Sep 30, 2023$140.06M-46.7%
Q2 FY2023Jun 30, 2023$169.34M-40.5%
Q1 FY2023Mar 31, 2023$197.88M-36.4%
Q4 FY2022Dec 31, 2022$228.47M+7.9%
Q3 FY2022Sep 30, 2022$262.65M+13.8%
Q2 FY2022Jun 30, 2022$284.61M+9.9%
Q1 FY2022Mar 31, 2022$310.96M+32.5%
Q4 FY2021Dec 31, 2021$211.72M-19.7%
Q3 FY2021Sep 30, 2021$230.82M+1.1%
Q2 FY2021Jun 30, 2021$258.92M+0.3%
Q1 FY2021Mar 31, 2021$234.70M-18.7%
Q4 FY2020Dec 31, 2020$263.74M-15.1%
Q3 FY2020Sep 30, 2020$228.36M-27.9%
Q2 FY2020Jun 30, 2020$258.24M-24.3%
Q1 FY2020Mar 31, 2020$288.79M+23.9%
Q4 FY2019Dec 31, 2019$310.57M+19.9%
Q3 FY2019Sep 30, 2019$316.76M+18.0%
Q2 FY2019Jun 30, 2019$341.16M+26.2%
Q1 FY2019Mar 31, 2019$233.03M+80.5%
Q4 FY2018Dec 31, 2018$259.09M+88.4%
Q3 FY2018Sep 30, 2018$268.40M–
Q2 FY2018Jun 30, 2018$270.31M–
Q1 FY2018Mar 31, 2018$129.08M–
Q4 FY2017Dec 31, 2017$137.53M–

More Q32 Bio figures

See a number that looks wrong?